What are the indications, dosing, monitoring, contraindications, and adverse effects of angiotensin‑converting enzyme (ACE) inhibitors for hypertension, heart failure with reduced ejection fraction, post‑myocardial infarction remodeling, and diabetic nephropathy, and what alternatives can be used if they are not tolerated?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 20, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

ACE Inhibitors: Clinical Guide

ACE inhibitors are first-line therapy for heart failure with reduced ejection fraction, post-myocardial infarction with LV dysfunction, diabetic nephropathy, and hypertension with diabetes or coronary artery disease, with proven mortality reduction across these conditions.

Indications

Class I (Strongest Evidence)

Heart Failure with Reduced Ejection Fraction (HFrEF)

  • All symptomatic patients with LVEF ≤40% should receive ACE inhibitors indefinitely 1, 2, 3
  • Even asymptomatic patients with documented LV systolic dysfunction benefit from long-term therapy 1
  • Reduces mortality, hospitalizations, and improves functional capacity 1, 2

Post-Myocardial Infarction

  • Start early in all patients with signs/symptoms of heart failure after acute MI, even if transient 1
  • Mandatory in patients with anterior MI, previous MI, or Killip class II findings 4, 5
  • Continue indefinitely in all post-MI patients with LVEF ≤40% 4, 5

Diabetic Nephropathy

  • First-line for type 1 diabetic nephropathy 6
  • Type 2 diabetic nephropathy with microalbuminuria or proteinuria 6, 7
  • Reduces progression to overt nephropathy by 24% 6

Coronary Artery Disease with Diabetes

  • All patients with CAD (documented by angiography or previous MI) who have diabetes should receive ACE inhibitors 6
  • Reduces cardiovascular death by 37%, MI by 22%, and stroke by 33% 6

Class IIa (Reasonable)

  • All patients with CAD or other vascular disease, even without diabetes 6
  • Lower-risk patients with normal LVEF after revascularization 4, 5
  • Hypertension management, particularly with target organ damage 8, 9

Dosing

Starting and Target Doses

Always start low and titrate to target doses proven in clinical trials 1, 2, 3:

Drug Starting Dose Target Dose
Enalapril 2.5 mg twice daily 10-20 mg twice daily
Lisinopril 2.5-5 mg once daily 20-40 mg once daily
Ramipril 1.25-2.5 mg once daily 10 mg once daily
Captopril 6.25 mg three times daily 50 mg three times daily
Perindopril 2 mg once daily 8-16 mg once daily
Trandolapril 1 mg once daily 4 mg once daily

Titration Protocol 1, 2

  1. Start at lower dose level
  2. Increase dose every 1-2 weeks if tolerated
  3. Target the maximum doses used in clinical trials—these are the doses that saved lives
  4. Do not stop at lower doses just because symptoms improve

Critical Point: The mortality benefit in trials was achieved at target doses, not at symptom-controlled doses 3.

Monitoring

Renal Function and Electrolytes 1, 2

Check creatinine and potassium:

  • Before starting
  • 1-2 weeks after each dose increment
  • At 3-6 month intervals during maintenance
  • When adding other RAAS agents (ARB, aldosterone antagonist)
  • During any hospitalization

Acceptable Changes 2

  • Modest creatinine increase (up to 20%) is expected and acceptable
  • eGFR decrease up to 15% is tolerable
  • Small blood pressure reductions are normal in normotensive patients

When to Discontinue or Reduce Dose 2

  • eGFR decreases >15%
  • Creatinine increases >20%
  • Potassium >5.5 mEq/L
  • Symptomatic hypotension unresponsive to dose adjustment

Contraindications

Absolute (Class III) 1, 2

  • Bilateral renal artery stenosis
  • History of angioedema with previous ACE inhibitor therapy
  • Pregnancy (all trimesters)
  • Current angioedema from any cause

Relative Cautions 9, 10

  • Severe renal impairment (creatinine >2.5 mg/dL in men, >2.0 mg/dL in women)
  • Baseline potassium >5.0 mEq/L
  • Severe aortic stenosis
  • Hypotension (SBP <90 mmHg)

Adverse Effects

Common (5-10% of patients) 1, 2

Dry Cough

  • Occurs in 5-10% of patients, more common in Chinese patients (up to 50%) 2
  • Nonproductive with persistent throat "tickle"
  • Appears within first months of therapy
  • Disappears 1-2 weeks after discontinuation
  • Management: Exclude pulmonary congestion first; if cough is tolerable, continue therapy given mortality benefit; if intolerable, switch to ARB 2

Hypotension

  • Usually small decreases in normotensive patients 1
  • More common with first dose in volume-depleted patients
  • Management: Ensure adequate hydration, reduce diuretic dose temporarily, give ACE inhibitor at bedtime

Hyperkalemia

  • Monitor closely, especially with concurrent aldosterone antagonists or ARBs 2
  • Risk increases with renal dysfunction

Serious but Rare (<1%) 2

Angioedema

  • Life-threatening emergency
  • More frequent in Black patients
  • Absolute contraindication to all future ACE inhibitor use
  • ARBs may be used with extreme caution (cross-reactivity possible) 2

Renal Insufficiency

  • Acute worsening possible, especially with bilateral renal artery stenosis
  • Usually reversible with discontinuation

Hypoglycemia 10

  • Not widely recognized but can occur in patients on glucose-lowering medications
  • Monitor glucose more closely when initiating ACE inhibitors in diabetics

Alternatives When ACE Inhibitors Not Tolerated

First Alternative: Angiotensin Receptor Blockers (ARBs) 2, 5

Use ARBs if:

  • Intolerable cough on ACE inhibitor (Class I indication) 1, 2
  • Angioedema on ACE inhibitor (use with extreme caution—cross-reactivity possible) 2
  • LVEF ≤40% with heart failure or post-MI 5

ARB Dosing for HFrEF 2, 3:

  • Candesartan: 4-8 mg once daily, target 32 mg once daily
  • Losartan: 25-50 mg once daily, target 50-100 mg once daily
  • Valsartan: 20-40 mg twice daily, target 160 mg twice daily

Important: ARBs have similar risks of hypotension, hyperkalemia, and renal dysfunction as ACE inhibitors 2. Angioedema is much less frequent but still possible 2.

Second Alternative: Hydralazine-Isosorbide Dinitrate 2, 3

Use if ACE inhibitors AND ARBs are contraindicated or not tolerated 2

Dosing 3:

  • Start: 20 mg isosorbide dinitrate + 37.5 mg hydralazine three times daily
  • Target: 40 mg isosorbide dinitrate + 75 mg hydralazine three times daily

Special consideration: Particularly effective in Black patients with NYHA class III-IV heart failure (43% mortality reduction) 3

Third Alternative: Angiotensin Receptor-Neprilysin Inhibitor (ARNi) 11, 3

Sacubitril-valsartan is now preferred over ACE inhibitors for HFrEF 11, 3:

  • Start: 49 mg sacubitril/51 mg valsartan twice daily
  • Target: 97 mg sacubitril/103 mg valsartan twice daily
  • Provides 16% additional mortality reduction beyond ACE inhibitors 3
  • Do not use within 36 hours of last ACE inhibitor dose (angioedema risk)

Combination Therapy Considerations

ACE Inhibitor + ARB 2, 8

Not routinely recommended 2, 8

  • May modestly reduce hospitalizations 2
  • Increases risk of hypotension, hyperkalemia, and renal dysfunction 8
  • If used, requires careful monitoring 8
  • Never combine all three: ACE inhibitor + ARB + aldosterone antagonist 2

ACE Inhibitor + Beta-Blocker + Aldosterone Antagonist + SGLT2 Inhibitor 11, 3

This is the current "four pillars" approach for HFrEF 11, 3:

  • All four should be initiated and titrated rapidly
  • Each provides independent mortality benefit
  • Monitor potassium and renal function closely with aldosterone antagonist added

Special Populations

Renal Impairment 1, 10, 12

  • Dose reduction required when creatinine clearance <30 mL/min 12
  • Exception: Fosinopril has dual hepatic/renal elimination—may not require dose adjustment 12, 13
  • Lisinopril preferred in liver disease (renal excretion only) 12

Acute Heart Failure 1, 13

  • Initiate carefully with low doses
  • Maintain or add diuretic therapy
  • Captopril may be preferred for first-dose due to rapid onset and short duration (allows quick reversal if hypotension occurs) 13

Diabetes with CKD 7, 10, 14

  • ACE inhibitors remain first-line unless severe renal dysfunction
  • Contraindicated if creatinine >2.5 mg/dL (men) or >2.0 mg/dL (women) 5
  • Monitor for hypoglycemia 10

Key Clinical Pearls

  1. Target doses matter: Don't settle for symptom control at low doses—titrate to trial-proven target doses for mortality benefit 3

  2. Cough is common but manageable: Encourage continuation if tolerable given survival benefit; only switch to ARB if truly intolerable 2

  3. Modest creatinine rise is acceptable: Up to 20% increase is expected and does not require discontinuation 2

  4. Angioedema is absolute contraindication: Never rechallenge with any ACE inhibitor; use ARBs with extreme caution 2

  5. Start early post-MI: Initiate within days of MI in appropriate patients for maximum benefit 1, 4

  6. Monitor potassium closely: Especially when combining with aldosterone antagonists or in renal impairment 1, 2

  7. ARNi is now preferred over ACE inhibitors for HFrEF when tolerated 11, 3

References

Research

[Comparative evaluation of ACE inhibitors: which differences are relevant?].

Schweizerische medizinische Wochenschrift, 1999

Research

Critical assessment of ACE inhibitors. Part 2.

Australian family physician, 1995

Related Questions

In adult patients requiring an ACE inhibitor for hypertension, heart failure, or diabetic kidney protection, which is preferred, enalapril or lisinopril?
In a patient with decompensated heart failure being treated with an ACE inhibitor (ACEi), an angiotensin receptor blocker (ARB) or angiotensin receptor‑neprilysin inhibitor (ARNI), and a mineralocorticoid receptor antagonist (MRA), what management steps are recommended if the estimated glomerular filtration rate falls to 15 mL/min/1.73 m²?
What is the preferred ACE inhibitor for most adult patients and how do other ACE inhibitors compare for hypertension, heart failure, post‑myocardial infarction remodeling, renal protection in diabetes, and acute hypertensive emergencies?
What is the recommended initial dose, titration schedule, target dose, monitoring parameters, and contraindications for using enalapril in an adult with systolic (reduced‑ejection‑fraction) heart failure?
Which angiotensin-converting enzyme (ACE) inhibitor should be initiated for a patient with hypertension, including recommended starting dose, titration schedule, and monitoring parameters?
What is the appropriate management for a patient with a 14‑day Zio (ambulatory ECG) showing 18 episodes of supraventricular tachycardia (SVT) lasting up to 14 seconds at a rate of 114 bpm?
Can capsaicin cream be used together with lidocaine 5% patches, and how should they be applied?
What is the appropriate management for a 6-year-old with a large painful swelling behind the left ear and a positive streptococcal test?
How should generalized anxiety disorder (GAD) be treated?
Which blood tests should be included in a panel to evaluate and diagnose anemia?
Should metoprolol be restarted in a patient who was tapered off due to bradycardia and now has a permanent pacemaker after third-degree atrioventricular block?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.